Cytoreductive Surgery With HIPEC for Abdominal Cancers

Cytoreductive surgery with HIPEC combines aggressive tumor removal with a heated chemotherapy wash delivered directly into the abdominal cavity, and it remains one of the few treatment strategies that can offer long-term survival for cancers that have spread to the peritoneum. The approach works best for specific tumor types and carefully selected patients, and the evidence supporting it varies sharply depending on the cancer involved. What looked like a broadly promising technique a decade ago has since been refined by landmark trials into something more targeted, with clear wins for some diseases and surprising question marks for others.

What the Procedure Actually Involves

The surgery portion, called cytoreductive surgery (CRS), aims to remove every visible tumor deposit from the surfaces lining the abdominal cavity. Depending on how far the disease has spread, the surgeon may need to strip the peritoneum from multiple regions and remove portions of affected organs. One widely referenced framework describes up to six distinct peritonectomy procedures that may be needed to clear all affected surfaces, including removal of the greater omentum and spleen, stripping of the left and right upper quadrant peritoneum, clearing the lesser omentum and gallbladder with stripping of the omental bursa, pelvic peritonectomy with partial sigmoid colon removal, and partial stomach removal.¹ Not every patient requires all of these steps. The extent depends on where and how much disease has taken hold.

After the surgeon has removed all visible tumor, the HIPEC phase begins. A heated chemotherapy solution, typically warmed to around 41–43°C, is circulated throughout the open abdominal cavity for 30 to 90 minutes, depending on the drug and protocol. The heat itself is selectively damaging to cancer cells, amplifies the killing power of certain chemotherapy drugs, and helps the drugs penetrate deeper into tissue.² The entire operation, combining the surgical debulking and the chemotherapy bath, can last anywhere from six to twelve hours.

Why Deliver Chemotherapy Directly Into the Abdomen

The peritoneum has a natural barrier that limits how much intravenous chemotherapy actually reaches tumors on its surface. By delivering drugs directly into the abdominal cavity, concentrations at the tumor site jump dramatically. A pharmacokinetic study of cisplatin found that drug exposure inside the abdominal cavity during HIPEC was roughly ten times higher than what the same drug achieved in the bloodstream when given intravenously.³ That is a massive pharmacological advantage, and it comes with a trade-off: systemic side effects are lower because less drug enters the general circulation.

The heated solution also helps by exploiting a vulnerability of cancer cells. Malignant cells are less able to repair heat-induced damage to their proteins and DNA than normal cells. The combination of heat plus direct drug exposure creates a one-two punch that intravenous chemotherapy alone cannot replicate on peritoneal surfaces.

Ovarian Cancer and the Strongest Evidence

The clearest survival benefit comes from advanced ovarian cancer. The landmark OVHIPEC-1 trial randomized patients with stage III epithelial ovarian cancer who were undergoing interval cytoreductive surgery (surgery performed after initial rounds of systemic chemotherapy) to receive either surgery alone or surgery plus HIPEC with cisplatin. The results were striking. Median overall survival was about 45 months in the HIPEC group compared with roughly 33 months in the surgery-alone group, and the risk of death was reduced by about 30%.⁴ Recurrence-free survival also improved, from about 11 months to about 14 months. Importantly, severe complication rates were similar between the two groups, meaning the HIPEC addition did not substantially increase surgical risk.⁵

The final survival analysis confirmed these long-term benefits, and the trial’s authors stated that the results support using HIPEC in patients with primary stage III epithelial ovarian cancer undergoing interval surgery.⁶ Economic analyses have also found that adding HIPEC to cytoreductive surgery in ovarian cancer appears cost-effective when measured against standard willingness-to-pay thresholds.⁷

Pseudomyxoma Peritonei and Mesothelioma

Some of the earliest and most dramatic successes of CRS with HIPEC came in rare cancers. Pseudomyxoma peritonei, a condition where mucin-producing tumors fill the abdominal cavity (often originating from appendiceal tumors), responds particularly well. Five-year overall survival rates depend on the aggressiveness of the disease: patients with the most indolent form (acellular mucin) had a five-year survival of 93%, while those with intermediate-grade disease (DPAM) reached about 70%, and those with the most aggressive form (PMCA) had a five-year survival around 55%.⁸ For a disease that was once considered untreatable, these are remarkable numbers. A Chinese series looking specifically at patients with incomplete tumor removal also found that adding HIPEC improved outcomes: five-year survival was 58% with HIPEC versus 48% without, and ten-year survival was 37% versus 16%.⁹

Peritoneal mesothelioma, another rare malignancy, has also shown encouraging results. One study of patients who underwent complete cytoreduction followed by HIPEC reported a median overall survival of about 63 months, with the survival curve flattening after seven years, at which point roughly 44% of patients with sufficient follow-up were still alive.¹⁰ That plateau suggests a subset of patients may be effectively cured, something almost unheard of for mesothelioma treated with systemic therapy alone.

The Colorectal Cancer Controversy

For years, colorectal cancer with peritoneal spread was considered one of the main indications for CRS with HIPEC, based on earlier observational data and one randomized trial from the early 2000s. Then the PRODIGE 7 trial upended the field. This French phase 3 trial randomized patients with colorectal peritoneal metastases to receive either cytoreductive surgery plus HIPEC (using oxaliplatin) or cytoreductive surgery alone. After more than five years of follow-up, median overall survival was virtually identical: about 42 months in both groups.¹¹ Meanwhile, patients who received HIPEC had more late complications: about 26% experienced severe adverse events at 60 days, compared with 15% in the surgery-alone group.

The trial’s conclusion was blunt: cytoreductive surgery alone should be the backbone of curative-intent treatment for colorectal peritoneal metastases. But the story is more nuanced than that headline suggests. Critics have pointed to several methodological and pharmacological issues with the trial, including the choice of oxaliplatin (which may have been partially neutralized by prior FOLFOX chemotherapy many patients had received), an unusually short HIPEC perfusion time, and inadequate concurrent fluorouracil dosing.¹² Some experts have argued that the trial tested a suboptimal HIPEC protocol rather than the concept itself, and suggested that switching to a different drug, such as mitomycin C, or modifying the protocol could yield different results. New trials are being designed to test these alternatives.

What PRODIGE 7 did confirm, however, is that the cytoreductive surgery itself was enormously valuable. A median survival of about 42 months for colorectal peritoneal metastases treated with complete surgical removal, with or without HIPEC, was far better than historical outcomes with systemic chemotherapy alone. The surgery clearly matters; the added value of the heated bath is what’s in question for this particular cancer.

Gastric Cancer and Emerging Evidence

Gastric cancer with peritoneal spread carries a dismal prognosis, and the evidence for CRS with HIPEC here is still evolving. The German GASTRIPEC-I trial randomized patients with gastric cancer and synchronous peritoneal metastases to surgery with or without HIPEC. Median overall survival was the same in both groups at about 15 months, though progression-free survival favored the HIPEC arm at roughly 7 months versus 3.5 months.¹³ The trial was underpowered because enrollment was difficult, so the final word has not been spoken. Retrospective data from larger cohorts has shown longer survival when HIPEC is added, but retrospective studies are inherently less reliable.¹⁴ An interesting direction for gastric cancer is prophylactic HIPEC, given during primary stomach cancer surgery before peritoneal metastases have appeared, on the theory that prevention is easier than cure. Trials in France and Germany are currently investigating this approach.

How Patients Are Selected

Not everyone with peritoneal cancer is a candidate for this procedure. The selection process is rigorous because the operation is long, physically demanding, and only beneficial when the surgeon can remove enough tumor to make the HIPEC worthwhile. Several factors drive the decision.

The peritoneal cancer index (PCI), a scoring system that quantifies how much tumor is present across 13 abdominal regions, is one of the most important tools. A study found that the intraoperative PCI score was the single best predictor of whether complete tumor removal was achievable, with a PCI threshold of around 20 correctly identifying cases where complete removal was and wasn’t possible with high accuracy.¹⁵ For colorectal cancer, an international expert consensus identified five major criteria guiding the decision: age, PCI, completeness of cytoreduction, extent of disease outside the peritoneum, and additional risk factors. Experts agreed that HIPEC should generally be avoided in older patients with a high tumor burden and in patients where complete cytoreduction is not achievable.¹⁶

The completeness of cytoreduction is the dominant determinant of outcomes across nearly all tumor types. If the surgeon cannot remove all visible disease, or at least reduce it to deposits smaller than about 2.5 millimeters, the benefit of HIPEC drops sharply. Tumor biology also matters: signet ring cell cancers, for example, tend to do poorly regardless of how thorough the surgery is.¹⁷

Recovery and Quality of Life

The recovery is no small matter. This is one of the most extensive operations in abdominal surgery, and the addition of heated chemotherapy creates physiological stress that goes beyond what a typical long surgery produces. Most patients experience a significant dip in quality of life in the first three months. In one study, global health scores dropped from about 69 out of 100 before surgery to about 57 at three months, then returned to near-baseline levels by 12 months. Physical function followed a similar trajectory, dropping from about 86 to 73 at three months and recovering by six months.¹⁸

Another study noted that between a third and half of patients reported depressive symptoms at various points during the first year, and pain scores peaked in the early postoperative months before dropping below baseline later on. Emotional well-being, interestingly, improved significantly after the procedure, possibly reflecting the psychological relief of having addressed the cancer aggressively.¹⁹ The overall picture is that quality of life takes a real hit early but recovers well for most patients within the first year.

How Enhanced Recovery Programs Help

One of the most practical advances in the field has been the adoption of Enhanced Recovery After Surgery (ERAS) protocols, which bundle evidence-based perioperative strategies like early mobilization, optimized pain control, reduced fasting, and careful fluid management. A meta-analysis found that ERAS implementation was associated with a reduction in hospital stay of about three days and a 40% lower risk of severe (grade III/IV) complications.²⁰ Individual center studies have echoed these findings, with one reporting average hospital stays dropping from about 10 days to 7 days after ERAS implementation, and severe complication rates declining from roughly 39% to 24%.²¹ Readmission rates did not change, suggesting that the shorter stays were not discharging patients prematurely.

Open Abdomen Versus Closed Technique

When the HIPEC solution is circulated, surgeons use one of two main approaches. The “open” or “coliseum” technique keeps the abdomen open, with the edges of the incision suspended on a retractor frame while the surgeon manually distributes the heated solution across all surfaces. The “closed” technique seals the abdomen temporarily and circulates the solution through drainage tubes. Each has trade-offs. The closed approach maintained more stable abdominal temperatures in one comparative study.²² However, pharmacokinetic work comparing open and laparoscopic-assisted (closed) delivery of oxaliplatin found that the drug crossed the peritoneal barrier faster in the closed technique, meaning more of it entered the bloodstream rather than staying where it was wanted.²³ No randomized trial has definitively settled which approach is superior, and many centers choose based on surgeon experience and patient factors.

Cost-Effectiveness

CRS with HIPEC is expensive upfront. The operation is long, requires specialized teams, involves extended hospital stays, and uses costly chemotherapy agents. But when weighed against the alternative of indefinite palliative chemotherapy for a disease that will eventually prove fatal, the economics often favor the surgical approach. A study from Singapore found that the cost per life year for CRS plus HIPEC was about S$21,000, compared with roughly S$59,000 per life year for palliative chemotherapy, because the surgical patients lived much longer.²⁴ A U.S.-based analysis of colorectal peritoneal carcinomatosis found the treatment cost-effective at conventional willingness-to-pay thresholds in the majority of simulated scenarios.²⁵

Pressurized Aerosol Chemotherapy as an Alternative

A newer approach called PIPAC (pressurized intraperitoneal aerosol chemotherapy) delivers chemotherapy as a fine mist into the pressurized abdominal cavity, typically during a minimally invasive laparoscopic procedure. The concept is appealing because it could offer more uniform drug distribution across the peritoneal surface and is far less invasive than CRS with HIPEC.²⁶ PIPAC is primarily used for patients who are not candidates for cytoreductive surgery, either because their disease is too extensive or because they cannot tolerate a major operation. It is increasingly being studied as a bridge therapy to make patients eligible for CRS with HIPEC later, and as a palliative treatment to control symptoms and potentially improve survival in otherwise untreatable disease. Head-to-head comparisons with HIPEC are still early-stage, and the two approaches currently serve somewhat different patient populations rather than directly competing.

Combining Heat With Immunotherapy

One of the more exciting areas of research involves the immune effects of the hyperthermia component of HIPEC. Experimental work has shown that heat exposure alone can trigger cancer cells to display signals that make them more visible to the immune system, including increased expression of surface markers that immune cells use to identify threats and the release of danger signals that activate immune responses. In an animal model of peritoneal metastases from colorectal cancer, hyperthermia alone prolonged survival compared with no treatment, and when combined with an immune checkpoint inhibitor (anti-PD-1), it produced the greatest survival benefit, comparable to full HIPEC combined with the same checkpoint drug.²⁷ The checkpoint inhibitor alone, without prior heat treatment, had no effect. This suggests heat may “prime” tumors to respond to immunotherapies they would otherwise ignore, opening a potential new avenue for combining CRS/HIPEC with systemic immune checkpoint inhibitors.

This immunological dimension is still preclinical, but it offers a biological rationale for why HIPEC may do more than just deliver hot chemotherapy. If the heat itself is remodeling the tumor’s immune environment, there could be synergies with immunotherapy drugs that are not yet being exploited in standard protocols.